Journal profile · Hematology
Experimental Hematology
ISSN 0301-472X · eISSN 1873-2399 · Elsevier Inc. · UNITED STATES · Monthly · Founded 1973
Experimental Hematology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.62; hybrid open access; APC about USD 3,250; median 91 days to acceptance (89 articles, last 24 months); community-reported acceptance: fairly easy (Elsevier website: 57%); 413 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Experimental Hematology is published by Elsevier Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research and Mesenchymal stem cell research, together about 33.8% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Journal for Hematology, Stem Cell Biology and TransplantationOfficial publication of the ISEH - International Society for Experimental HematologyExperimental Hematology publishes new findings, methodologies, reviews and perspectives in all areas of hematology and immune cell formation on a monthly basis and may include Special Issues on particular topics of current interest. The overall goal is to report new insights into how normal blood cells are produced, how their production is normally regulated, mechanisms that contribute to hematological diseases and new approaches to their treatment.Articles will be published under the following scientific categories:Stem CellsExperimental Stem Cell TransplantationNormal HematopoiesisMalignant HematopoiesisMicroenvironment and NicheSystems BiologyGenomics/Proteomics of HematopoiesisImmunobiology and ImmunotherapyGene TherapyClinical InvestigationsNew Techniques and TechnologiesExperimental Hematology publishes two types of articles: Reviews and Perspectives and original findings sub-classified either as Brief Communications of significant singular results and Research Articles presenting the results of more developed studies.Experimental Hematology publishes Special Issues dedicated to important topics in the field. To view our Special Issues and article collections, click here.
From the journal's Aims & Scope
Research area (LetPub): Hematology
Editor-in-chief Toshio SudaPublisher website
Editorial board by country: 3 in mainland China (about 8%); most named United States 13, United Kingdom 7, Japan 5, Mainland China 3, Spain 2 (38 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Hematopoietic Stem Cell TransplantationMedicine14.9%
- Acute Myeloid Leukemia ResearchMedicine13.1%
- Mesenchymal stem cell researchMedicine5.9%
- Immune Cell Function and InteractionImmunology and Microbiology4.6%
- T-cell and B-cell ImmunologyImmunology and Microbiology4.2%
- Erythrocyte Function and PathophysiologyMedicine4.1%
- Zebrafish Biomedical Research ApplicationsBiochemistry, Genetics and Molecular Biology3.9%
- Chronic Myeloid Leukemia TreatmentsMedicine3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedPublisher website
Other: Crossref
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.62LetPub ·
- Impact factor (publisher)
- 2.7Publisher website ·
- CiteScore 2026-06
- 4LetPub ·
- CiteScore (publisher)
- 4Publisher website ·
- SJR 2026-06
- 0.96LetPub ·
- SNIP 2026-06
- 0.53LetPub ·
- h-index
- 114LetPub ·
- h-index
- 142OpenAlex ·
- i10-index
- 2,720OpenAlex ·
- 2-year mean citedness
- 0.84OpenAlex ·
- Self-citation rate
- 11.1%LetPub ·
- Share of gold OA articles
- 35.14%LetPub ·
Volume
- Articles per year
- 71LetPub ·
Articles by year OpenAlex count · 8,303 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 65 | 30 | 16 |
| 2025 | 413 | 72 | 213 |
| 2024 | 379 | 379 | 492 |
| 2023 | 373 | 373 | 582 |
| 2022 | 374 | 374 | 671 |
| 2021 | 286 | 286 | 1,371 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
91 daysMedian, submission to acceptance · P25–P75 47 days – 148 days
- Acceptance to online
- median 9 days (89 articles)
- Submission to online
- median 101 days
- Sample
- 89 articles with submission and acceptance dates (179 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- 57%LetPub ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,250 / EUR 3,040 / GBP 2,600 / JPY 403,100 | — | — | |
| Publisher website | USD 3,500 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Submission fee
- USD 50
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare8 items from the author guidelines
- Abstract
- ≤ 250 words
- Manuscript length
- ≤ 3,600 words
- Reference style
- Author–date
- Templates
- Word
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Optional
- Highlights
- Required
- Graphical abstract
- Optional
Article types accepted11, with length limits
- brief communicationOriginal Article: These are full-length reports of original research. We welcome articles on a broad range of topics, with particular emphasis on:regulation and…main text ≤ 1,500 words
- brief communicationsBrief Communications: We also welcome articles on the same range of topics as outlined for regular submissions, but that can be reported in a shorter format.Length not stated
- commentaryeditorial review prior to publication. Commentaries must not exceed 1,000 words long, including a short abstract not exceeding 100 words. Tmain text ≤ 1,000 words · abstract ≤ 100 words · references ≤ 10
- editorialthe Experimental Hematology field. Each Editorial is limited to a maximum of 4,000 words. One figure or table is optional but encouraged. Fast-Trackmain text ≤ 4,000 words
- exphem insightsExpHem Insights: Submissions in this category should present impactful findings, including reports of phenomenologies (with exploration of potential mechanisms …Length not stated
- original articleOriginal Article: These are full-length reports of original research. We welcome articles on a broad range of topics, with particular emphasis on:regulation and…main text ≤ 4,000 words
- original researchOriginal Article: These are full-length reports of original research. We welcome articles on a broad range of topics, with particular emphasis on:regulation and…Length not stated
- protocolOriginal Article: These are full-length reports of original research. We welcome articles on a broad range of topics, with particular emphasis on:regulation and…Length not stated
- reviewEach submitted manuscript will normally undergo peer review by at least two editorial board members or other experts designated by the editor-in-chief or associ…Length not stated
- reviewsReviews: Review Articles summarize topics of interest to Experimental Hematology's broad readership and/or discuss significant topics and controversies relevant…Length not stated
- standards in hematologyStandards in Hematology: This category includes articles that provide best practices and methodologies, offering a dedicated platform or rigorously validated te…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI in scientific writing
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Authorship
Submission fee of US $50 for Regular Submissions Model summary
All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.
Source ↗Publisher website ·- Conflicts of interest Conflict of interest policy
A conflict of interest exists when an author, reviewer, or editor has financial or personal relationships with other persons or organizations that may inappropriately influence or bias his or her actions. There is a potential for a conflict of interest whether or not an individual believes that a relationship affects his or her scientific judgment. Conflicts can occur as the result of employment, …
Source ↗Publisher website ·- License & copyright Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.Subscribers may reproduce tables of contents or prepare lists of articles includ…
Source ↗Publisher website ·- Open access Open access
Open access publication fee payable Model summary
Please visit our Open Access page for more information about open access publishing in this journal.• Articles are freely available to both subscribers and the wider public with permitted reuse• An open access publication fee is payable by authors or their research funderSubscription•Articles are made available to subscribers as well as developing countries and patient groups through our access pr…
Source ↗Publisher website ·- Peer review Review process and policies
Single anonymized review process Model summary
Each submitted manuscript will normally undergo peer review by at least two editorial board members or other experts designated by the editor-in-chief or associate editor in charge of the manuscript's review. Authors' names will be seen by reviewers, but reviewers' names will not be disclosed to the authors. A paper can be rejected without undergoing the peer review process if the editor determine…
Source ↗Publisher website ·- Preprints Preprint references
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the nam…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1973
- ISSN
- 0301-472X
- Electronic ISSN
- 1873-2399
- Society / sponsor
- ISEH - International Society for Experimental Hematology
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Experimental Hematology
What CAS zone is Experimental Hematology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Experimental Hematology is in Zone 4 of Medicine, and in Zone 4 of the minor category Hematology / Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Experimental Hematology?
The latest impact factor listed by LetPub is 2.62; CiteScore 4, h-index 142.
How long does peer review take at Experimental Hematology?
Based on the dates recorded on 89 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 91 days (interquartile range 47–148 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Fairly easy (Elsevier website: 57%)”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Experimental Hematology?
According to the journal's author guidelines: Abstract: ≤ 250 words; Manuscript length: ≤ 3,600 words; Reference style: Author–date; Templates: Word; First submission: Free format: the journal's layout is not required; Suggested reviewers: Optional; Highlights: Required; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Experimental Hematology based?
Of the 38 board members whose country the journal's board page names, 3 (about 8%) are in mainland China; the countries named most often are United States (13), United Kingdom (7) and Japan (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Experimental Hematology?
According to LetPub and DOAJ records, Experimental Hematology is indexed in SCIE and Scopus. The journal's website also lists PubMed; that list has not been checked against each database.
Is Experimental Hematology open access, and what is the APC?
Experimental Hematology is a hybrid journal. For open-access publication: APC about USD 3,250.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .